To better understand how blocking NHE1 protein activity modulates metabolic dysregulation of GAMs, we performed bulk RNA-seq and profiled the transcriptome of isolated tumor-associated CD11b+ cells from GL26 glioma tumors that had undergone the four treatment regimens (Veh, HOE642, TMZ or T+H combination therapy, Fig. 4A). The gene discussed is SLC9A1; the disease is central nervous system cancer.